Companies / Contineum Therapeutics, Inc. / Activity
Activity — Contineum Therapeutics, Inc.
39 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | Stengone Carmine N. CEO | Sell | Class A Common Stock | $70.5K | -4K -22.73% | 14,954 0.04% of shares | low |
| Feb 24, 2026 | Lorrain Daniel S. Executive | Sell | Class A Common Stock | $68.9K | -4K -2.68% | 156,052 0.41% of shares | low |
| Mar 2, 2026 | Lorrain Daniel S. Executive | Sell | Class A Common Stock | $62.6K | -4K -2.67% | 151,882 0.40% of shares | low |
| Feb 25, 2026 | Lorrain Daniel S. Executive | Sell | Class A Common Stock | $61.2K | -4K -2.39% | 156,052 0.41% of shares | low |
| Mar 2, 2026 | Watkins Tim Executive | Sell | Class A Common Stock | $54.2K | -4K -100.00% | 0 0.00% of shares | low |
| Feb 3, 2026 | Lorrain Daniel S. Executive | Sell | Class A Common Stock | $44.5K | -3K -1.87% | 157,222 0.42% of shares | low |
| Feb 25, 2026 | Stengone Carmine N. CEO | Sell | Class A Common Stock | $43.2K | -3K -15.29% | 14,954 0.04% of shares | low |
| Jan 28, 2026 | Watkins Tim Executive | Sell | Class A Common Stock | $39.4K | -3K -77.54% | 811 <0.01% of shares | low |
| Jan 5, 2026 | Lorrain Daniel S. Executive | Sell | Class A Common Stock | $38.0K | -4K -2.23% | 160,722 0.43% of shares | low |
| Feb 3, 2026 | Lorrain Daniel S. Executive | Sell | Class A Common Stock | $17.8K | -1K -0.74% | 156,052 0.41% of shares | low |
| Mar 2, 2026 | Watkins Tim Executive | Exercise | Class A Common Stock | $16.2K | +4K | 3,611 <0.01% of shares | low |
| Jan 28, 2026 | Watkins Tim Executive | Exercise | Class A Common Stock | $16.2K | +4K | 3,611 <0.01% of shares | low |
| Jan 28, 2026 | Watkins Tim Executive | Sell | Class A Common Stock | $11.7K | -811 -100.00% | 0 0.00% of shares | low |
| Feb 11, 2026 | Stengone Carmine N. CEO | Sell | Class A Common Stock | $6.4K | -400 -2.61% | 14,954 0.04% of shares | low |
| Feb 11, 2026 | Lorrain Daniel S. Executive | Sell | Class A Common Stock | $6.4K | -400 -0.26% | 156,052 0.41% of shares | low |
| Jan 5, 2026 | Lorrain Daniel S. Executive | Sell | Class A Common Stock | $5.6K | -500 -0.31% | 160,222 0.43% of shares | low |
| Feb 24, 2026 | Stengone Carmine N. CEO | Exercise | Class A Common Stock | $5.5K | +4K +29.42% | 19,354 0.05% of shares | low |
| Feb 24, 2026 | Lorrain Daniel S. Executive | Exercise | Class A Common Stock | $4.3K | +4K +2.76% | 160,352 0.43% of shares | low |
| Feb 25, 2026 | Lorrain Daniel S. Executive | Exercise | Class A Common Stock | $3.9K | +4K +2.45% | 159,876 0.42% of shares | low |
| Feb 25, 2026 | Stengone Carmine N. CEO | Exercise | Class A Common Stock | $3.4K | +3K +18.06% | 17,654 0.05% of shares | low |
| Feb 19, 2026 | Lorrain Daniel S. Executive | Sell | Class A Common Stock | $1.6K | -100 -0.06% | 156,052 0.41% of shares | low |
| Feb 11, 2026 | Stengone Carmine N. CEO | Exercise | Class A Common Stock | $504 | +400 +2.67% | 15,354 0.04% of shares | low |
| Feb 11, 2026 | Lorrain Daniel S. Executive | Exercise | Class A Common Stock | $404 | +400 +0.26% | 156,452 0.42% of shares | low |
| Feb 19, 2026 | Lorrain Daniel S. Executive | Exercise | Class A Common Stock | $101 | +100 +0.06% | 156,152 0.42% of shares | low |
| Mar 2, 2026 | Watkins Tim Executive | Exercise | Stock Option (right to buy) | — | -4K -1.43% | 249,167 0.66% of shares | low |
| Feb 25, 2026 | Stengone Carmine N. CEO | Exercise | Stock Option (right to buy) | — | -3K -2.18% | 120,917 0.32% of shares | low |
| Feb 24, 2026 | Stengone Carmine N. CEO | Exercise | Stock Option (right to buy) | — | -4K -3.44% | 123,617 0.33% of shares | low |
| Feb 25, 2026 | Lorrain Daniel S. Executive | Exercise | Stock Option (right to buy) | — | -4K -5.38% | 67,306 0.18% of shares | low |
| Feb 24, 2026 | Lorrain Daniel S. Executive | Exercise | Stock Option (right to buy) | — | -4K -5.70% | 71,130 0.19% of shares | low |
| Feb 19, 2026 | Lorrain Daniel S. Executive | Exercise | Stock Option (right to buy) | — | -100 -0.13% | 75,430 0.20% of shares | low |
| Feb 11, 2026 | Stengone Carmine N. CEO | Exercise | Stock Option (right to buy) | — | -400 -0.31% | 128,017 0.34% of shares | low |
| Feb 11, 2026 | Lorrain Daniel S. Executive | Exercise | Stock Option (right to buy) | — | -400 -0.53% | 75,530 0.20% of shares | low |
| Jan 30, 2026 | Healy John Stephen Executive | Grant | Stock Option (right to buy) | — | +206K | 206,411 0.55% of shares | low |
| Jan 30, 2026 | Stengone Carmine N. CEO | Grant | Stock Option (right to buy) | — | +445K | 445,000 1.18% of shares | low |
| Jan 30, 2026 | Lorrain Daniel S. Executive | Grant | Stock Option (right to buy) | — | +7K | 6,500 0.02% of shares | low |
| Jan 30, 2026 | Lorrain Daniel S. Executive | Grant | Stock Option (right to buy) | — | +160K | 160,000 0.43% of shares | low |
| Jan 30, 2026 | Watkins Tim Executive | Grant | Stock Option (right to buy) | — | +160K | 160,000 0.43% of shares | low |
| Jan 28, 2026 | Watkins Tim Executive | Exercise | Stock Option (right to buy) | — | -4K -1.41% | 252,778 0.67% of shares | low |
| Jan 30, 2026 | Slover Peter T Executive | Grant | Stock Option (right to buy) | — | +192K | 192,000 0.51% of shares | low |